Addiction treatment in Michigan

Three things shape whether a person in Michigan can access treatment: where they live in the state, what insurance they carry, and which clinician answers the first call. The 788 licensed facilities do not change that calculus; they constrain the choices within it.

The Medicaid question

Michigan expanded Medicaid in 2014 under the Affordable Care Act. This single policy decision shapes access more than any other single factor. Has realistic access to Medicaid coverage for addiction treatment once enrolled. The states that expanded tend to see meaningfully higher treatment engagement; the states that did not tend to push low-income adults into the state-funded margin, where capacity runs out faster than demand.

The overdose-mortality context

The CDC puts Michigan's 2023 overdose mortality at 28.3 per 100,000. Whether that number is going up or down week-to-week matters less than where it concentrates, which is uneven: Upper Peninsula isolation plus Detroit-area fentanyl concentration

How access actually works in Michigan

Inside the 788 licensed facilities in Michigan, the clinical quality variation is substantial. The practical context here is that Upper Peninsula isolation plus Detroit-area fentanyl concentration — which is why the difference between a well-run IOP and a fee-for-service residential chain that churns patients through 30-day cycles is not visible from the outside. It becomes visible when you ask the specific question: "Does this program offer buprenorphine for opioid use disorder?"

What to do next

In Michigan, the most underused resource is the PCP. Primary care has expanded its role in addiction treatment substantially since 2020 — buprenorphine prescribing, naltrexone administration, referrals into the evidence-based portion of the network — and a 30-minute PCP appointment often produces more useful direction than a 30-minute call with a treatment-center admissions counselor whose incentives are commercial.